Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Inhibikase Therapeutics (IKT) Interest Coverage Ratio (2020 - 2022)

Inhibikase Therapeutics (IKT) has disclosed Interest Coverage Ratio for 3 consecutive years, with 928119.2 as the latest value for Q1 2022.

  • On a quarterly basis, Interest Coverage Ratio fell 416962.55% to 928119.2 in Q1 2022 year-over-year; TTM through Dec 2022 was 3625721.6, a 489095.22% decrease, with the full-year FY2021 number at 741.16, down 673.17% from a year prior.
  • Interest Coverage Ratio was 928119.2 for Q1 2022 at Inhibikase Therapeutics, down from 31907.98 in the prior quarter.
  • In the past five years, Interest Coverage Ratio ranged from a high of 52.08 in Q2 2020 to a low of 928119.2 in Q1 2022.
  • A 3-year average of 109939.28 and a median of 222.54 in 2021 define the central range for Interest Coverage Ratio.
  • Peak YoY movement for Interest Coverage Ratio: tumbled 205.98% in 2021, then plummeted 416962.55% in 2022.
  • Inhibikase Therapeutics' Interest Coverage Ratio stood at 168.21 in 2020, then crashed by 18869.2% to 31907.98 in 2021, then plummeted by 2808.74% to 928119.2 in 2022.
  • Per Business Quant, the three most recent readings for IKT's Interest Coverage Ratio are 928119.2 (Q1 2022), 31907.98 (Q4 2021), and 28477.96 (Q3 2021).